Advertisement
UK markets close in 4 hours 1 minute
  • FTSE 100

    8,069.48
    +45.61 (+0.57%)
     
  • FTSE 250

    19,734.94
    +135.55 (+0.69%)
     
  • AIM

    754.01
    +4.83 (+0.64%)
     
  • GBP/EUR

    1.1610
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2390
    +0.0040 (+0.32%)
     
  • Bitcoin GBP

    53,347.48
    +115.08 (+0.22%)
     
  • CMC Crypto 200

    1,422.06
    +7.30 (+0.52%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    81.47
    -0.43 (-0.53%)
     
  • GOLD FUTURES

    2,314.70
    -31.70 (-1.35%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    18,076.65
    +215.85 (+1.21%)
     
  • CAC 40

    8,105.13
    +64.77 (+0.81%)
     

Coronavirus vaccine makers to testify before U.S. House committee

FILE PHOTO: A small bottle labeled with a "Vaccine" sticker is held near a medical syringe in front of displayed "Coronavirus COVID-19" words in this illustration

(Reuters) - Five companies developing coronavirus vaccines will testify before a sub-committee of the U.S. House Of Representatives later this month, sharing information about their research and development efforts.

Officials from Merck & Co Inc, Moderna, Pfizer Inc, AstraZeneca and Johnson & Johnson will testify on July 21, the House Committee of Energy and Commerce said on Thursday. (https://bit.ly/2AOuVfi)

"This hearing will provide an opportunity for both Congress and the American people to hear directly from some of the manufacturers currently developing potential COVID-19 vaccines," the committee said.

The five companies, alongside several others, are racing to develop vaccines for COVID-19, caused by the novel coronavirus, and the United States has poured billions in funding some of them to secure access to vaccines should they work.

ADVERTISEMENT

At the hearing, the companies are also expected to share information about their preparations to manufacture and distribute an eventual vaccine.

None of the five companies immediately responded to Reuters' request for a comment.

(Reporting by Manas Mishra and Vishwadha Chander in Bengaluru; Editing by Shinjini Ganguli)